Subscribe or Manage Preferences

Rheumatoid Arthritis

By Phoebe Starr After achieving low disease activity (LDA) while receiving full-dose induction etanercept (Enbrel) therapy at 36 weeks, patients with moderately active rheumatoid arthritis (RA) can be maintained on half-dose etanercept instead of full-dose etanercept for a further 52 weeks...
By Wayne Kuznar Routine screening for replicating JC polyomavirus (JCPyV) or serum antibodies does not seem to be warranted in rheumatic patients treated with rituximab (Rituxan).
New oral therapies, such as Janus kinase (JAK) inhibitors and spleen tyrosine kinase inhibitors, will be challenged to break the grip on the market held by the leading large-molecule therapies in the treatment of rheumatoid arthritis (RA).
Page 9 of 9
Results 81 - 83 of 83
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology